Search

Displaying results 5661 - 5670 of 8697 in total
  1. Drug

    Technetium Tc-99m ciprofloxacin

    go.drugbank.com/drugs/DB05488
    Experimental

    99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  2. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.

  3. Drug

    BNC105

    go.drugbank.com/drugs/DB06313
    Investigational

  4. Drug

    Pentaerythritol tetranitrate

    go.drugbank.com/drugs/DB06154
    ApprovedWithdrawn

    Interestingly, this drug was studied for potential benefits in chronic ischemic heart failure patients. … It is formed by reacting pentaerythritol (C5H12O4), an alcohol commonly used in paints and varnishes, with nitric acid (HNO2). The reacting solution is chilled to precipitate the PETN.

  5. Drug

    Enokizumab

    go.drugbank.com/drugs/DB05555
    Investigational

    A humanized immunoglobulin G1k anti-interleukin-9 mAb.

  6. Drug

    VIR201

    go.drugbank.com/drugs/DB05110
    Experimental

    is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.

  7. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19.

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Calcitonin gene-related peptide

    go.drugbank.com/drugs/DB06379
    Investigational

    As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties

  9. Drug

    Tecadenoson

    go.drugbank.com/drugs/DB04954
    Investigational

    Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

    Categories: Purinergic P1 Receptor Agonists
  10. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [A264514] Xanomeline is a muscarinic agonist that was approved for the treatment of schizophrenia by the FDA in September 2024, becoming the first approved treatment for schizophrenia to target muscarinic

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates